← Leaderboards
Estuardo Aguilar-Cordova
Advantagene, Inc
$12,245,489
Attributed
$13,394,789
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$13,394,789 · 5
By mechanism
R44$12,422,406 · 3
R43$972,383 · 2
Top collaborators
- Laura K Aguilar5 shared
Most similar at Advantagene, Inc
Same institution · by research overlap
- Laura K Aguilar$1,149,301
- Madhu Chhikara$100,000
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchGrantDoseToxic EffectSafetyRadiationProtocols DocumentationMeasurableTumorProdrugsQuality Of LifeRecurrenceMediatingBaseCytotoxicNovel TherapeuticsChemotherapyImmuneGenesCessation Of LifeClinical ProtocolsImmunotherapyOperative Surgical ProceduresResponse
Grant awards (18)
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2021 · CA · contact PI
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2020 · CA · contact PI
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$116,400
R44 · FY2019 · CA · contact PI
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$659,516
R44 · FY2018 · CA · contact PI
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$299,985
R44 · FY2016 · CA · contact PI
Clinically suitable approach for gene-mediated therapy of cirrhosis.$224,999
R43 · FY2014 · AA · contact PI
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,857,725
R44 · FY2013 · CA · contact PI
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,917,582
R44 · FY2012 · CA · contact PI
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,902,504
R44 · FY2011 · CA · contact PI
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,473,388
R44 · FY2009 · CA · contact PI
Clinical study of AdV-tk radiogene therapy for malignant glioma$510,001
R44 · FY2009 · CA · contact PI
Clinical study of AdV-tk radiogene therapy for malignant glioma$794,415
R44 · FY2008 · CA · contact PI
Clinical study of AdV-tk radiogene therapy for malignant glioma$788,188
R44 · FY2007 · CA · contact PI
Clinical study of GMCI in Pancreatic Cancer$376,666
R43 · FY2007 · CA · contact PI
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$101,130
R44 · FY2007 · CA · contact PI
Clinical study of GMCI in Pancreatic Cancer$370,718
R43 · FY2006 · CA · contact PI
Clinical study of AdV-tk radiogenetherapy for malignant*$402,041
R44 · FY2005 · CA
Clinical study of AdV-tk radiogene therapy for glioma$376,831
R44 · FY2004 · CA